Rezende Paulo Cury, Hueb Whady, Rahmi Rosa Maria, Scudeler Thiago Luis, de Azevedo Diogo Freitas Cardoso, Garzillo Cibele Larrosa, Segre Carlos Alexandre Wainrober, Ramires Jose Antonio Franchini, Filho Roberto Kalil
Heart Institute (InCor) of the University of São Paulo, Avenida Dr. Eneas de Carvalho Aguiar, 44, AB sala 114, Cerqueira César, São Paulo, SP CEP 05403-900 Brazil.
Diabetol Metab Syndr. 2017 Nov 21;9:92. doi: 10.1186/s13098-017-0292-3. eCollection 2017.
Diabetic patients may be more susceptible to myocardial injury after coronary interventions. Thus, the aim of this study was to assess the release of cardiac biomarkers, CK-MB and troponin, and the findings of new late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) in patients with type 2 diabetes mellitus after elective revascularization procedures for multivessel coronary artery disease (CAD).
Patients with multivessel CAD and preserved systolic ventricular function underwent either elective percutaneous coronary intervention (PCI), off-pump or on-pump bypass surgery (CABG). Troponin and CK-MB were systematically collected at baseline, 6, 12, 24, 36, 48 and 72 h after the procedures. CMR with LGE was performed before and after the interventions. Patients were stratified according to diabetes status at study entry. Biomarkers and CMR results were compared between diabetic and nondiabetics patients. Analyses of correlation were also performed among glycemic and glycated hemoglobin (A1c) levels and troponin and CK-MB peak levels. Patients were also stratified into tertiles of fasting glycemia and A1c levels and were compared in terms of periprocedural myocardial infarction (PMI) on CMR.
Ninety (44.5%) of the 202 patients had diabetes mellitus at study entry. After interventions, median peak troponin was 2.18 (0.47, 5.14) and 2.24 (0.69, 5.42) ng/mL ( = 0.81), and median peak CK-MB was 14.1 (6.8, 31.7) and 14.0 (4.2, 29.8) ng/mL ( = 0.43), in diabetic and nondiabetic patients, respectively. The release of troponin and CK-MB over time was statistically similar in both groups and in the three treatments, besides PCI. New LGE on CMR indicated that new myocardial fibrosis was present in 18.9 and 17.3% ( = 0.91), and myocardial edema in 15.5 and 22.9% ( = 0.39) in diabetic and nondiabetic patients, respectively. The incidence of PMI in the glycemia tertiles was 17.9% versus 19.3% versus 18.7% ( = 0.98), and in the A1c tertiles was 19.1% versus 13.3% versus 22.2% ( = 0.88).
In this study, diabetes mellitus did not add risk of myocardial injury after revascularization interventions in patients with multivessel coronary artery disease. Name of Registry: Evaluation of cardiac biomarker elevation after percutaneous coronary intervention or coronary artery bypass graft; URL: http://www.controlled-trials.com.ISRCTN09454308.
糖尿病患者在冠状动脉介入治疗后可能更容易发生心肌损伤。因此,本研究的目的是评估2型糖尿病患者在接受多支冠状动脉疾病(CAD)的择期血运重建手术后,心脏生物标志物肌酸激酶同工酶(CK-MB)和肌钙蛋白的释放情况,以及心脏磁共振成像(CMR)上新出现的晚期钆增强(LGE)表现。
多支冠状动脉疾病且收缩期心室功能保留的患者接受了择期经皮冠状动脉介入治疗(PCI)、非体外循环或体外循环冠状动脉旁路移植术(CABG)。在术前、术后6、12、24、36、48和72小时系统收集肌钙蛋白和CK-MB。在干预前后进行带LGE的CMR检查。根据研究入组时的糖尿病状态对患者进行分层。比较糖尿病患者和非糖尿病患者的生物标志物及CMR结果。还对血糖和糖化血红蛋白(A1c)水平与肌钙蛋白和CK-MB峰值水平进行了相关性分析。患者还被分为空腹血糖和A1c水平三分位数,并就CMR上的围手术期心肌梗死(PMI)情况进行比较。
202例患者中有90例(44.5%)在研究入组时患有糖尿病。干预后,糖尿病患者和非糖尿病患者的肌钙蛋白峰值中位数分别为2.18(0.47,5.14)和2.24(0.69,5.42)ng/mL(P = 0.81),CK-MB峰值中位数分别为14.1(6.8,31.7)和14.0(4.2,29.8)ng/mL(P = 0.43)。除PCI外,两组以及三种治疗方式中肌钙蛋白和CK-MB随时间的释放情况在统计学上相似。CMR上新出现的LGE表明,糖尿病患者和非糖尿病患者中新发心肌纤维化的比例分别为18.9%和17.3%(P =